Chinese red @entity375 @entity579 @entity263 growth in XXXX @entity19 .

@entity1 @entity263 @entity5 @entity19 @entity915 @entity579 @entity342 @entity375 @entity925 @entity165
@entity263 is a slowly developing but very common @entity5 in males that may be amenable to preventive strategies that are not toxic. Chinese red @entity375 @entity579 (RYR), a food herb made by fermenting Monascus purpureus Went @entity375 on white @entity579 , contains a mixture of eight different monacolins that inhibit cholesterogenesis in addition to red pigments with antioxidant properties. Monacolin K is identical to lovastatin (LV), but LV unlike RYR can be used in individuals intolerant to statins due to @entity925 . Both LV and RYR inhibit de novo cholesterogenesis, which is critical to the growth of @entity5 cells. Long-term use of statin drugs has been associated with a reduced risk of @entity263 . We have previously shown that RYR inhibited @entity342 -dependent and @entity342 receptor-overexpressing @entity342 -independent @entity263 cell proliferation in vitro. This study was designed to determine whether RYR and @entity263 growth in @entity915 @entity19 . RYR significantly reduced @entity5 volumes of @entity342 -dependent and @entity342 -independent prostate xenograft @entity5 compared with animals receiving vehicle alone (P < 0.05). Inhibition by RYR was greater than that observed with LV at the dose found in RYR, showing that other compounds in RYR contributed to the antiproliferative effect. There was a significant correlation of @entity5 volume to serum @entity165 (P < 0.001). RYR decreased gene expression of @entity342 synthesizing enzymes (HSD3B2, AKR1C3, and SRD5A1) in both type of @entity5 (P < 0.05). Clinical studies of RYR for @entity263 prevention in the increasing population of @entity1 undergoing active surveillance should be considered.
